Business
Currency:CNY
2023/FY
Stock NameRevenueRatio
Drug sales5.97B90.42%
Income from extension services591.41M8.95%
许可收入28.47M0.43%
Revenue from R & D services13M0.20%
Product
No Data
Region
No Data